Effects of icosapent ethyl (Eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of omeprazole and rosiglitazone in healthy subjects.

Trial Profile

Effects of icosapent ethyl (Eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of omeprazole and rosiglitazone in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary) ; Omeprazole; Rosiglitazone
  • Indications Hypertriglyceridaemia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Amarin Corporation
  • Most Recent Events

    • 26 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top